NP
ALDX icon

NorthRock Partners’s Aldeyra Therapeutics ALDX Stock Holding History

NorthRock Partners’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,951
Closed -$41.9K – 815
2023
Q4 		$41.9K Buy
+11,951
New +$36.9K ﹤0.01% 630

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

NorthRock Partners's ALDX Position: Q1 2024 in Review

NorthRock Partners sold out of Aldeyra Therapeutics (ALDX) in Q1 2024, closing a stake of 11,951 shares — an estimated $41.9K sold.

NorthRock Partners first reported a position in ALDX in Q4 2023 and held it in 1 quarter. The position peaked at $41.9K in Q4 2023. 102 funds tracked by Wall St. Rank hold ALDX as of Q1 2024.

  • NorthRock Partners reported no remaining Aldeyra Therapeutics position as of Q1 2024 after selling out during the quarter.
  • NorthRock Partners sold 11,951 Aldeyra Therapeutics shares in Q1 2024, an estimated $41.9K.
  • NorthRock Partners first reported a position in Aldeyra Therapeutics in Q4 2023 and held it in 1 quarter.
  • NorthRock Partners's Aldeyra Therapeutics position peaked at $41.9K in Q4 2023.
  • 102 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2024.

Based on NorthRock Partners's 13F filing for Q1 2024, filed 7 May 2024.